Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Does anyone have a good email address for John?
October 1st and no mention of what seems to be the lateness of the final $1mil payment. That’s just a bit troubling.
Market cap of $2.33Mil. Definitely not trading like a company that’s soon to drop $3Mil in the kitty. $1mil from SLB and $2Mil from utility order.
“Estimated to be completed by September 2018” hmmmm? Where’s the final $1mil payment?
September. Tic-Toc $1mil.... Tic-Toc
Not trading like a company about to pocket $3mill
Repricing those options was some real B.S.
If you want them to have value get the darn stock back above $0.20 where they were originally priced. Taking them all the down to $0.01 was criminal.
Also if I remember correctly there are huge amounts of stock options they granted themselves @$0.20 and then re priced the strike to $0.01
You’re right..... just not enough eyeballs on this good news
PR for $2mil order to a utilities co and a 10q stating the final $1mil payment should come by September can’t get this stock above $0.08 ..........Sad
Valuation? Say the $1mil final payment and the $2mil utilities sale hits the bank..... what should the company trade at? CEO accrued salary seems to be an overhang
So the final $1million should be in the bank by September?
Up some 90%. However, disappointed with the price action and volume considering the news and were the stock has been
EVTN Transitions into Industrial Wastewater; Announces Order from Utility Company https://finance.yahoo.com/news/evtn-transitions-industrial-wastewater-announces-123100122.html
Oh Snap! EVTN transitions into industrial wastewater; Announces order from utility company!!
I wouldn’t think so. That looks like a much bigger machine
However, they are handing out 1 million share pats on the back
No new is not good news
Gifting! LOL!
Under 0.05 cents. I guess this is what happens when you hand out 1million shares of company stock to you and your buddy when the last $1mil payment appears to be past due
1 year and counting. Where’s the last $1mil?
I find the timing of this stock issuance incredibly suspicious considering we are 1 week away from the 1 year anniversary of the Schlumberger deal. If by chance the final $1M payment isn’t made then I’m not sure the issuance is appropriate. If on the other hand the payment is made next week the stock should rise. Let’s say payment is made and the stock goes to 0.10...... then if you want to give yourself $50k you’d be getting 500,000 shares each and not 1M. Shareholders are being diluted
I’m not sure what the going rate is. However, John is paying Veldman $12k per year to sit on the board and rubber stamp their mutual admiration society
The boys have been busy. Issued themselves 2M shares of common stock as a pat on the back for the 2017 Schlumberger deal. 1M each to John Dibella and Veldman at a cost of 0.05 each or $50K
Isn’t it about time for final $1mil payment?
Back to 0.04 it is - 01/09/18 Very Strange
Rocket to 0.20 or Slow burn back to 0.04?
Well that was fun. Now back to low or no volume and the sound of crickets.
No recent insider buys
Haha! Something is afoot for sure. Nobody drops $250k on a hunch.
Frightening in the way they sold the technology to Schlumberger for $3mil
And retained the manufacturing rights for 2 years and sales outside oil and gas?
Nobody spends $250,000 for a OTCBB stock on a whim
Enviro Bolckchain Technologies - Maybe they’re about to change their name.
So there’s about 33million shares outstanding so they make about $0.03cents per share for every $1million they make. Now throw some type of multiple on that say 10X and you’ll get $0.30cents.
Back of the envelope calculation
What is this new drug you’re studying?
Dr. Chang: This new treatment modality that we’re studying is very new, cutting edge and very exciting. It’s a new paradigm in cancer treatment. What it involves is a product called TNFerade, which is a tumor necrosis factor that is delivered by a virus into the cancer. The background of this is that our immune cells produce TNF, which is a cytokine protein that has anti-tumor properties. It kills cancer cells, but in small quantities. It’s produced in small quantities by our immune cells. So, the concept is that if we took the TNF and injected large quantities into the patient, the toxicity would be overwhelming. The challenge is to produce TNF inside the cancer cell and only in the cancer cells and not in the normal cells. What has been designed then for this therapy is to take the human TNF alpha gene and place that gene into a virus. The virus is also especially engineered not to replicate and cause viral illness. So, the virus is a vehicle to deliver the gene. That has been delivered to the tumor through yet another breakthrough in terms of a medical technology with endoscopic ultrasound. Endoscopic ultrasound is a scope that goes into the body, into the stomach, just like a routine endoscopy, but it allows us to see through the stomach into the tumor and we can then place a needle through the endoscope and deliver the virus directly into the tumor working from within the stomach and GI tract. Once we deliver the virus into the tumor, we deliver four times 10 to the ninth to four times 10 to the 11th viral particles. These viruses then spread among the cancer cells and attach to the cancer cells. Once it attaches, the TNF from the virus, the TNF gene from the virus is actually injected into the cancer cells and that’s what viruses do very well.
Once the TNF gene is injected into the cancer cell, the virus itself does not replicate and dies off. So, it’s done its kamikaze mission, and it’s delivered the TNF. When the TNF is in the cancer cell, it will start to replicate and produce TNF. The TNF will then destroy the cancer cell.
Now, this therapy also works in synergy with chemotherapy and radiation therapy, so it’s actually a combined synergistic modality. So, what happens is that the patient receives chemotherapy and this is the standard 5FU chemotherapy, which has anti-tumor effect as well as causes the tumor to be more radiation sensitive. Then the patient receives radiation, and the radiation has anti-tumor effect. The radiation also has a special effect on the TNF gene. It causes the TNF gene to replicate much faster, so it steps on the gas pedal. So now the TNF is being produced in larger quantities. The TNF has anti-tumor properties, and it also is a radiation sensitizer, so you can see that three different modalities, all synergistically, each one makes the other more potent and more powerful, so you have a really strong combination in this combined therapy.
So it is used in combination with these others, but for a reason? That’s designed very much that way.
Dr. Chang: That’s right. It’s designed in combination with chemotherapy and radiation therapy to active in synergy, as opposed to just an add-on, ABC, off-the-menu type thing.
Now how does the TNF that you’ve injected react after it’s worked on cancer? Does it die off eventually?
Dr. Chang: The TNF, the gene for TNF is in the cancer cell and the cancer cell itself will produce TNF. Then the TNF will destroy the cancer cell. There may be some spillover once the cancer cell is destroyed, but the half-life of TNF is rather short, and the chance of it spreading throughout the body is very small. During the trial, we measured the serum blood level of TNF, and it’s not detectable in most patients.
http://www.ivanhoe.com/channels/p_channelstory.cfm?storyid=7686
A Safer, Better Vaccine
Another important FMD development
from PIADC is the world’s first effective
molecular-based FMD vaccine for cattle,
developed by chemist Marvin Grubman
and colleagues. The vaccine can be produced
without using infectious FMD
materials, which means it can be produced
safely, in the United States, without
expensive, high-containment facilities.
Another benefit is that animals
vaccinated with Grubman’s vaccine don’t
produce all the antibodies that infected
animals produce. Because of this, they
can easily be distinguished. Most existing
vaccines cause animals to produce the
same antibodies as infected animals,
making it difficult to determine whether
an animal with antibodies was naturally
infected or vaccinated.
ARS—in collaboration with the U.S.
Department of Homeland Security’s Targeted
Advanced Development unit and
GenVec, Inc., a biopharmaceutical company
based in Gaithersburg, Maryland—is
developing this technology for potential
commercialization.
Tests have shown that the vaccine becomes
effective a mere 7 days after it’s
been administered. Although this is one
of the fastest vaccines available, Grubman
and his colleagues wanted faster
protection. After all, a lot can happen in
7 days, particularly during an outbreak.
In a recent study, Grubman found that
interferons—proteins produced by the immune
system—can offer protection during
that first week.
Interferons are so named because they
interfere with virus replication. Grubman
and his colleagues introduced type I and
type II interferon genes into an adenovirus,
which they administered to groups
of pigs. One day later, they infected the
swine with FMD virus. The interferons
blocked FMD virus replication, offering
the swine protection.
“The interferon gives early protection
for 3 to 5 days while the animals are
developing an antibody response to
the vaccine,” Grubman says. “This
significantly increases their chances of
resisting FMD.”
ARS and GenVec are now collaborating
to combine the interferons and the FMD
vaccine so they can be administered
together
http://www.ars.usda.gov/is/AR/archive/apr09/disease0409.pdf
National Veterinary Stockpile by November 2009
Received pre-licensing from USDA Center for Veterinary Biologics for the first ever next-generation molecular vaccine for Foot and Mouth Disease virus to significantly improve the Nation’s ability to prevent, protect and mitigate the effects of an outbreak of FMD. The Foreign Animal Disease vaccines and diagnostics program is on schedule to have the vaccine fully licensed and ready for production by private industry and procurement to the National Veterinary Stockpile by November 2009. Technology used in the next-generation DIVA vaccine will also accelerate the speed at which new vaccines can be produced.
http://www.dhs.gov/ynews/testimony/testimony_1238089175289.shtm